The c-rel protooncogene encodes a member of the Rel/nuclear factor (NF)-κB family of transcriptional factors. To assess the role of the transcriptional activation domain of c-Rel in vivo, we generated mice expressing a truncated c-Rel (Δc-Rel) that lacks the COOH-terminal region, but retains a functional Rel homology domain. Mice with an homozygous mutation in the c-rel region encoding the COOH terminus of c-Rel (c-relΔCT/ΔCT) display marked defects in proliferative and immune functions. c-relΔCT/ΔCT animals present histopathological alterations of hemopoietic tissues, such as an enlarged spleen due to lymphoid hyperplasia, extramedullary hematopoiesis, and bone marrow hypoplasia. In older c-relΔCT/ΔCT mice, lymphoid hyperplasia was also detected in lymph nodes, liver, lung, and stomach. These animals present a more severe phenotype than mice lacking the entire c-Rel protein. Thus, in c-relΔCT/ΔCT mice, the lack of c-Rel activity is less efficiently compensated by other NF-κB proteins.
Skip Nav Destination
Article navigation
6 April 1998
Article|
April 06 1998
Multiple Hemopoietic Defects and Lymphoid Hyperplasia in Mice Lacking the Transcriptional Activation Domain of the c-Rel Protein
Daniel Carrasco,
Daniel Carrasco
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Janet Cheng,
Janet Cheng
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Anne Lewin,
Anne Lewin
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Glenn Warr,
Glenn Warr
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Hyekyung Yang,
Hyekyung Yang
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Cheryl Rizzo,
Cheryl Rizzo
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Fabio Rosas,
Fabio Rosas
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Clifford Snapper,
Clifford Snapper
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Rodrigo Bravo
Rodrigo Bravo
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Search for other works by this author on:
Daniel Carrasco
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Janet Cheng
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Anne Lewin
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Glenn Warr
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Hyekyung Yang
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Cheryl Rizzo
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Fabio Rosas
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Clifford Snapper
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Rodrigo Bravo
From the *Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000; the ‡Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute,Wallingford, Connecticut 06492; and the §Department of Pathology, Uniformed Services, University of Health Sciences, Bethesda, Maryland 20814
Address correspondence to Rodrigo Bravo, Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543. Phone: 609-252-5744; Fax: 609-252-6051; E-mail: bravo#m#[email protected]
1Abbreviations used in this paper: Δc-Rel, truncated c-Rel; CAT, chloramphenicol acetyl transferase; CD, cluster of differentiation; EMSA, electrophoretic mobility shift assay; ES, embryonic stem; GC, germinal center; Gr-1, granulocyte 1; LCMV, lymphocytic choriomeningitis virus; Mac-1, macrophage 1; mCD40L, ligand for the mouse CD40; NF, nuclear factor; p, protein; p(A), polyadenylation sequence; PGK, phosphoglycerate kinase; pPNT, plasmid PGK promoter neomycin thymidine kinase; RHD, Rel homology domain; Ter, total erythroid cells.
D. Carrasco's present address is Department of Pathology, Massachusetts General Hospital, Boston, MA 02114.
Received:
August 28 1997
Revision Received:
January 12 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 187 (7): 973–984.
Article history
Received:
August 28 1997
Revision Received:
January 12 1998
Citation
Daniel Carrasco, Janet Cheng, Anne Lewin, Glenn Warr, Hyekyung Yang, Cheryl Rizzo, Fabio Rosas, Clifford Snapper, Rodrigo Bravo; Multiple Hemopoietic Defects and Lymphoid Hyperplasia in Mice Lacking the Transcriptional Activation Domain of the c-Rel Protein . J Exp Med 6 April 1998; 187 (7): 973–984. doi: https://doi.org/10.1084/jem.187.7.973
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
